Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).

Abulkhair, O.Uslu, R.Sezgin, C.Bueyuekberber, S.Darwish, T.Isikdogan, A.Gumus, M.2024-04-242024-04-2420120008-54721538-7445https://doi.org/10.1158/0008-5472.SABCS12-OT1-1-08https://hdl.handle.net/11468/17925[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keyword]Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study).Conference Object72WOS:00020970490008310.1158/0008-5472.SABCS12-OT1-1-08Q1